Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-negative) after chemotherapy in the metastatic setting or recurrence during or within six months after completing adjuvant chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The action makes HER2-low a treatment-selection category separate from classic HER2-positive disease.
What research teams should watch
Record the underlying IHC score and ISH result rather than relying on a binary HER2 status field.
PRIMARY RECORDS